The bevacizumab experience in advanced renal cell carcinoma

References

• YagodaAPetrylakDThompsonSCytotoxic chemotherapy for advanced renal cell carcinomaUrol Clin North Am1993203033218493752
   PubMed Web of Science ®Google Scholar
• LonserRRGlennGMWaltherMvon Hippel-Lindau diseaseLancet20033612059206712814730
   PubMed Web of Science ®Google Scholar
• GallouCJolyDMejeanAMutations of the VHL gene in sporadic renal cell carcinoma: definition of a risk factor for VHL patients to develop an RCCHum Mutat19991346447510408776
   PubMed Web of Science ®Google Scholar
• GnarraJRToryKWengYMutations of the VHL tumour suppressor gene in renal carcinomaNat Genet1994785907915601
   PubMed Web of Science ®Google Scholar
• KimWKaelinWGJrThe von Hippel-Lindau tumor suppressor protein: new insights into oxygen sensing and cancerCurr Opin Genet Dev200313556012573436
   PubMed Web of Science ®Google Scholar
• KondoKYaoMYoshidaMComprehensive mutational analysis of the VHL gene in sporadic renal cell carcinoma: relationship to clinicopathological parametersGenes Chromosomes Cancer200234586811921283
   PubMed Web of Science ®Google Scholar
• SukosdFKurodaNBeotheTKaurAPKovacsGDeletion of chromosome 3p14.2–p25 involving the VHL and FHIT genes in conventional renal cell carcinomaCancer Res20036345545712543802
   PubMed Web of Science ®Google Scholar
• LatifFToryKGnarraJIdentification of the von Hippel-Lindau disease tumor suppressor geneScience1993260131713208493574
   PubMed Web of Science ®Google Scholar
• MaxwellPHWiesenerMSChangGWThe tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysisNature199939927127510353251
   PubMed Web of Science ®Google Scholar
• FerraraNGerberHPLeCouterJThe biology of VEGF and its receptorsNat Med2003966967612778165
   PubMed Web of Science ®Google Scholar
• LeungDWCachianesGKuangWJGoeddelDVFerraraNVascular endothelial growth factor is a secreted angiogenic mitogenScience1989246130613092479986
   PubMed Web of Science ®Google Scholar
• PrestaLGChenHO’ConnorSJHumanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disordersCancer Res199757459345999377574
   PubMed Web of Science ®Google Scholar
• Bevacizumab [package insert]. Genentech; 2009. South San Francisco, CA, USA.
   Google Scholar
• GordonMSMargolinKTalpazMPhase I safety and pharmacokinetic study of recombinant human anti-vascular endothelial growth factor in patients with advanced cancerJ Clin Oncol20011984385011157038
   PubMed Web of Science ®Google Scholar
• YangJCBevacizumab for patients with metastatic renal cancer: an updateClin Cancer Res2004106367S6370S15448032
   PubMed Web of Science ®Google Scholar
• YangJCHaworthLSherryRMA randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancerN Engl J Med200334942743412890841
   PubMed Web of Science ®Google Scholar
• ElarajDMWhiteDESteinbergSMA pilot study of antiangiogenic therapy with bevacizumab and thalidomide in patients with metastatic renal cell carcinomaJ Immunother20042725926415235386
   PubMed Web of Science ®Google Scholar
• D’AmatoRJLoughnanMSFlynnEFolkmanJThalidomide is an inhibitor of angiogenesisProc Natl Acad Sci U S A199491408240857513432
   PubMed Web of Science ®Google Scholar
• KenyonBMBrowneFD’AmatoRJEffects of thalidomide and related metabolites in a mouse corneal model of neovascularizationExp Eye Res1997649719789301478
   PubMed Web of Science ®Google Scholar
• EisenTBoshoffCMakIContinuous low dose thalidomide: a phase II study in advanced melanoma, renal cell, ovarian and breast cancerBr J Cancer20008281281710732751
   PubMed Web of Science ®Google Scholar
• EscudierBLassauNCouanetDPhase II trial of thalidomide in renal-cell carcinomaAnn Oncol2002131029103512176780
   PubMed Web of Science ®Google Scholar
• MinorDRMonroeDDamicoLAA phase II study of thalidomide in advanced metastatic renal cell carcinomaInvest New Drugs20022038939312448656
   PubMed Web of Science ®Google Scholar
• MotzerRJBergWGinsbergMPhase II trial of thalidomide for patients with advanced renal cell carcinomaJ Clin Oncol20022030230611773183
   PubMed Web of Science ®Google Scholar
• HainsworthJDSosmanJASpigelDRTreatment of metastatic renal cell carcinoma with a combination of bevacizumab and erlotinibJ Clin Oncol2005237889789616204015
   PubMed Web of Science ®Google Scholar
• CiardielloFCaputoRBiancoRInhibition of growth factor production and angiogenesis in human cancer cells by ZD1839 (Iressa), a selective epidermal growth factor receptor tyrosine kinase inhibitorClin Cancer Res200171459146511350918
   PubMed Web of Science ®Google Scholar
• RiedelFGotteKLiMHormannKGrandisJREGFR antisense treatment of human HNSCC cell lines down-regulates VEGF expression and endothelial cell migrationInt J Oncol200221111612063543
   PubMed Web of Science ®Google Scholar
• BukowskiRMKabbinavarFFFiglinRARandomized phase II study of erlotinib combined with bevacizumab compared with bevacizumab alone in metastatic renal cell cancerJ Clin Oncol2007254536454117876014
   PubMed Web of Science ®Google Scholar
• McDermottDFReganMMClarkJIRandomized phase III trial of high-dose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinomaJ Clin Oncol20052313314115625368
   PubMed Web of Science ®Google Scholar
• MotzerRJBacikJMurphyBARussoPMazumdarMInterferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinomaJ Clin Oncol20022028929611773181
   PubMed Web of Science ®Google Scholar
• EscudierBBellmuntJNegrierSPhase III trial of bevacizumab plus interferon alfa-2a in patients with metastatic renal cell carcinoma (AVOREN): f inal analysis of overall survivalJ Clin Oncol20101214412150
   Google Scholar
• EscudierBPluzanskaAKoralewskiPBevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trialLancet20073702103211118156031
   PubMed Web of Science ®Google Scholar
• RiniBIHalabiSRosenbergJEPhase III trial of bevacizumab plus interferon alfa versus interferon alfa monotherapy in patients with metastatic renal cell carcinoma: final results of CALGB 90206J Clin Oncol20102137214320368558
   PubMed Web of Science ®Google Scholar
• RiniBIHalabiSRosenbergJEBevacizumab plus interferon alfa compared with interferon alfa monotherapy in patients with metastatic renal cell carcinoma: CALGB 90206J Clin Oncol2008265422542818936475
   PubMed Web of Science ®Google Scholar
• RiniBIHalabiSTaylorJSmallEJSchilskyRLfor Cancer and Leukemia Group B 90206A randomized phase III trial of interferon-alpha or interferon-alpha plus anti-vascular endothelial growth factor antibody (bevacizumab) in metastatic renal cell carcinomaClin Cancer Res2004102584258615102658
   PubMed Web of Science ®Google Scholar
• MelicharBKoralewskiPRavaudAFirst-line bevacizumab combined with reduced dose interferon-alpha2a is active in patients with metastatic renal cell carcinomaAnn Oncol2008191470147618408224
   PubMed Web of Science ®Google Scholar
• MotzerRJEscudierBOudardSEfficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trialLancet200837244945618653228
   PubMed Web of Science ®Google Scholar
• DudekAZZolnierekJDhamALindgrenBRSzczylikCSequential therapy with sorafenib and sunitinib in renal cell carcinomaCancer2009115616719051290
   PubMed Web of Science ®Google Scholar
• EichelbergCHeuerRChunFKSequential use of the tyrosine kinase inhibitors sorafenib and sunitinib in metastatic renal cell carcinoma: a retrospective outcome analysisEur Urol2008541373137818692304
   PubMed Web of Science ®Google Scholar
• RiniBIMichaelsonMDRosenbergJEAntitumor activity and biomarker analysis of sunitinib in patients with bevacizumab-refractory metastatic renal cell carcinomaJ Clin Oncol2008263743374818669461
   PubMed Web of Science ®Google Scholar
• StadlerWMFiglinRAMcDermottDFSafety and efficacy results of the advanced renal cell carcinoma sorafenib expanded access program in North AmericaCancer12721161272128020082451
   PubMedGoogle Scholar
• TamaskarIGarciaJAElsonPAntitumor effects of sunitinib or sorafenib in patients with metastatic renal cell carcinoma who received prior antiangiogenic therapy [discussion 6]J Urol2008179818617997441
   PubMed Web of Science ®Google Scholar
• ZimmermannKSchmittelASteinerUSunitinib treatment for patients with advanced clear-cell renal-cell carcinoma after progression on sorafenibOncology20097635035419321976
   PubMed Web of Science ®Google Scholar
• AzadNSPosadasEMKwitkowskiVECombination targeted therapy with sorafenib and bevacizumab results in enhanced toxicity and antitumor activityJ Clin Oncol2008263709371418669456
   PubMed Web of Science ®Google Scholar
• FeldmanDRBaumMSGinsbergMSPhase I trial of bevacizumab plus escalated doses of sunitinib in patients with metastatic renal cell carcinomaJ Clin Oncol2009271432143919224847
   PubMed Web of Science ®Google Scholar
• RiniBIGarciaJACooneyMMA phase I study of sunitinib plus bevacizumab in advanced solid tumorsClin Cancer Res2009156277628319773375
   PubMed Web of Science ®Google Scholar
• HainsworthJDSpigelDRBurrisHAIIIPhase II trial of bevacizumab and everolimus in patients with advanced renal cell carcinomaJ Clin Oncol20102131213620368560
   PubMed Web of Science ®Google Scholar
• ZafarYBendellJLagerJPreliminary results of a phase I study of bevacizumab (BV) in combination with everolimus (E) in patients with advanced solid tumorsAmerican Society of Clinical Oncology Annual MeetingJune 2006Atlanta, GA
   Google Scholar
• BendellJCGeorgeDNixonAResults of a phase I study of bevacizumab (BV), everolimus (EV), and erlotinib (E) in patients with advanced solid tumorsAmerican Society of Clinical Oncology Annual MeetingJune 2007Chicago, IL
   Google Scholar
• GluskerPRechtLLaneBReversible posterior leukoencephalopathy syndrome and bevacizumab [discussion 2]N Engl J Med200635498098116510760
   PubMed Web of Science ®Google Scholar
• OzcanCWongSJHariPReversible posterior leukoencephalopathy syndrome and bevacizumab [discussion 2]N Engl J Med200635498098216514715
   PubMed Web of Science ®Google Scholar
• HincheyJChavesCAppignaniBA reversible posterior leukoencephalopathy syndromeN Engl J Med19963344945008559202
   PubMed Web of Science ®Google Scholar
• BibbJLLeeSLuDLeeFIncrease in systolic (SBP) and decrease in diastolic blood pressure (DBP) may predict clinical benefit (CB) of bevacizumab (B) in patients (PTS) with metastatic colorectal cancer (mCRC) treated with cytotoxic agents (CA) [abstract 450]ASCO Gastrointestinal Cancers SymposiumJanuary 2007Orlands, FL, USA
   Google Scholar
• DahlbergSESandlerABBrahmerJRSchillerJHJohnsonDHClinical course of advanced non-small-cell lung cancer patients experiencing hypertension during treatment with bevacizumab in combination with carboplatin and paclitaxel on ECOG 4599J Clin Oncol20102894995420085937
   PubMed Web of Science ®Google Scholar
• FribergGKKVokesEEKindlerHLEarly hypertension (HTN) as a potential pharmacodynamic (PD) marker for survival in pancreatic cancer (PC) patients (pts) treated with bevacizumab (B) and gemcitabine (G) [abstract 3020]Proceedings of Am Soc Clin Oncol2005 www.asco.org
   Google Scholar
• RiniBSchillerJFruehaufJPAssociation of diastolic blood pressure (dBP) > 90 mmHg with overall survival (OS) in patients treated with axitinib (AG-013736) [abstract 3543]J Clin Oncol200826 www.asco.org
   Web of Science ®Google Scholar
• ScartozziMGaliziaEChiorriniSArterial hypertension correlates with clinical outcome in colorectal cancer patients treated with first-line bevacizumabAnn Oncol20092022723018842611
   PubMed Web of Science ®Google Scholar
• SchneiderBPWangMRadovichMAssociation of vascular endothelial growth factor and vascular endothelial growth factor receptor-2 genetic polymorphisms with outcome in a trial of paclitaxel compared with paclitaxel plus bevacizumab in advanced breast cancer: ECOG 2100J Clin Oncol2008264672467818824714
   PubMed Web of Science ®Google Scholar
• ChoueiriTKSchutzFAJeYRosenbergJEBellmuntJRisk of arterial thromboembolic events with sunitinib and sorafenib: a systematic review and meta-analysis of clinical trialsJ Clin Oncol2010282280228520351323
   PubMed Web of Science ®Google Scholar
• ChuTFRupnickMAKerkelaRCardiotoxicity associated with tyrosine kinase inhibitor sunitinibLancet20073702011201918083403
   PubMed Web of Science ®Google Scholar
• KhakooAYKassiotisCMTannirNHeart failure associated with sunitinib malate: a multitargeted receptor tyrosine kinase inhibitorCancer20081122500250818386829
   PubMed Web of Science ®Google Scholar
• LenihanDJTyrosine kinase inhibitors: can promising new therapy associated with cardiac toxicity strengthen the concept of teamwork?J Clin Oncol2008265154515518838702
   PubMed Web of Science ®Google Scholar
• MotzerRJHutsonTETomczakPOverall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinomaJ Clin Oncol2009273584359019487381
   PubMed Web of Science ®Google Scholar
• MotzerRJHutsonTETomczakPSunitinib versus interferon alfa in metastatic renal-cell carcinomaN Engl J Med200735611512417215529
   PubMed Web of Science ®Google Scholar
• Sunitinib maleate [package insert]. Pfizer; 2010
   Google Scholar
• SchmidingerMZielinskiCCVoglUMCardiac toxicity of sunitinib and sorafenib in patients with metastatic renal cell carcinomaJ Clin Oncol2008265204521218838713
   PubMed Web of Science ®Google Scholar
• TelliMLWittelesRMFisherGASrinivasSCardiotoxicity associated with the cancer therapeutic agent sunitinib malateAnn Oncol2008191613161818436521
   PubMed Web of Science ®Google Scholar
• ForceTKrauseDSVan EttenRAMolecular mechanisms of cardiotoxicity of tyrosine kinase inhibitionNat Rev Cancer2007733234417457301
   PubMed Web of Science ®Google Scholar
• VeroneseMLMosenkisAFlahertyKTMechanisms of hypertension associated with BAY 43-9006J Clin Oncol2006241363136916446323
   PubMed Web of Science ®Google Scholar
• EreminaVJeffersonJAKowalewskaJVEGF inhibition and renal thrombotic microangiopathyN Engl J Med20083581129113618337603
   PubMed Web of Science ®Google Scholar
• SugimotoHHamanoYCharytanDNeutralization of circulating vascular endothelial growth factor (VEGF) by anti-VEGF antibodies and soluble VEGF receptor 1 (sFlt-1) induces proteinuriaJ Biol Chem2003278126051260812538598
   PubMed Web of Science ®Google Scholar
• BaoPKodraATomic-CanicMThe role of vascular endothelial growth factor in wound healingJ Surg Res200915334735819027922
   PubMed Web of Science ®Google Scholar
• HowdieshellTRCallawayDWebbWLAntibody neutralization of vascular endothelial growth factor inhibits wound granulation tissue formationJ Surg Res20019617318211266270
   PubMed Web of Science ®Google Scholar
• AminCWallenEPruthiRSPreoperative tyrosine kinase inhibition as an adjunct to debulking nephrectomyUrology20087286486818684493
   PubMed Web of Science ®Google Scholar
• CoweyCLAminCPruthiRSNeoadjuvant clinical trial with sorafenib for patients with stage II or higher renal cell carcinomaJ Clin Oncol1502281502150720159822
   PubMed Web of Science ®Google Scholar
• JonaschEWoodCGMatinSFPhase II presurgical feasibility study of bevacizumab in untreated patients with metastatic renal cell carcinomaJ Clin Oncol20092727
   Web of Science ®Google Scholar
• MargulisVMatinSFTannirNSurgical morbidity associated with administration of targeted molecular therapies before cytoreductive nephrectomy or resection of locally recurrent renal cell carcinomaJ Urol2008180949818485389
   PubMed Web of Science ®Google Scholar
• ThomasAARiniBIStephensonAJSurgical resection of renal cell carcinoma after targeted therapyJ Urol20091616
   Google Scholar
• WoodCGMargulisVNeoadjuvant (presurgical) therapy for renal cell carcinoma: a new treatment paradigm for locally advanced and metastatic diseaseCancer20091152355236019402066
   PubMed Web of Science ®Google Scholar
• RiniBITyrosine-kinase inhibitors in a presurgical settingPresentation at: 2009 American Society of Clinical Oncology’s Genitourinary Cancers SymposiumMarch 2009Ordando, FL, USA
   Google Scholar
• Sorafenib [package insert]. Bayer Pharmaceutical; 2009. Wayne, NJ, USA.
   Google Scholar
• EscudierBEisenTStadlerWMSorafenib in advanced clear-cell renal-cell carcinomaN Engl J Med200735612513417215530
   PubMed Web of Science ®Google Scholar
• EscudierBEisenTStadlerWMSorafenib for treatment of renal cell carcinoma: final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trialJ Clin Oncol2009273312331819451442
   PubMed Web of Science ®Google Scholar
• EscudierBSzczylikCHutsonTERandomized phase II trial of first-line treatment with sorafenib versus interferon alfa-2a in patients with metastatic renal cell carcinomaJ Clin Oncol2009271280128919171708
   PubMed Web of Science ®Google Scholar
• Votrient [prescribing information]. GlaxoSmithKline; 2010. Research Triangle, NC, USA.
   Google Scholar
• HutsonTEDavisIDMachielsJPEfficacy and safety of pazopanib in patients with metastatic renal cell carcinomaJ Clin Oncol20092847548020008644
   PubMed Web of Science ®Google Scholar
• SternbergCNDavisIDMardiakJPazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trialJ Clin Oncol2010281061106820100962
   PubMed Web of Science ®Google Scholar